Source:http://linkedlifedata.com/resource/pubmed/id/15566510
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2004-11-29
|
| pubmed:abstractText |
With the favorable result of interferon (IFN)-ribavirin combination therapy for 24 weeks among naive Taiwanese chronic hepatitis C (CHC) patients, the optimal regimens of re-treatment for CHC patients who failed initial IFN monotherapy is not well-established. The study evaluated the effectiveness of re-treatment for 24 weeks with 3 different regimens and predictors for sustained virological response (SVR). METHODS: Total 120 Taiwanese CHC patients (81 males, 70 relapsers, mean age: 48.6 years) who failed initial IFN monotherapy were enrolled. They were assigned randomly (with a ratio of 1:1:2) to receive one of the three regimens for re-treatment for 24 weeks; group A: IFN 6 million units (MU) monotherapy (N=30), group B: combination therapy with ribavirin and IFN 3 MU (N=30) or group C: combination therapy with ribavirin and IFN 6 MU (N=60). The intention-to-treat rate of sustained virological response (SVR) was 38.3%. The SVR rate in group C (53.3%) was significantly higher than group A (16.7%, P<0.005) and group B (30%, P<0.05). Drop-out rates were similar between the three groups. Patients achieving SVR had significant improvement histologically. Hepatitis C virus (HCV) genotype non-1b infection, lower pretreatment HCV RNA levels, combined with ribavirin and with higher IFN dose, and relapsers were independent predictors for SVR. CONCLUSION: We concluded that more than one-third Taiwanese CHC patients achieved SVR after 24 weeks re-treatment and combination therapy, especially with higher dose of IFN, yielded higher efficacy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1478-3223
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
24
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
595-602
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:15566510-Administration, Oral,
pubmed-meshheading:15566510-Adult,
pubmed-meshheading:15566510-Dose-Response Relationship, Drug,
pubmed-meshheading:15566510-Drug Administration Schedule,
pubmed-meshheading:15566510-Drug Therapy, Combination,
pubmed-meshheading:15566510-Female,
pubmed-meshheading:15566510-Follow-Up Studies,
pubmed-meshheading:15566510-Hepatitis C, Chronic,
pubmed-meshheading:15566510-Humans,
pubmed-meshheading:15566510-Injections, Subcutaneous,
pubmed-meshheading:15566510-Interferon-alpha,
pubmed-meshheading:15566510-Liver Function Tests,
pubmed-meshheading:15566510-Logistic Models,
pubmed-meshheading:15566510-Male,
pubmed-meshheading:15566510-Middle Aged,
pubmed-meshheading:15566510-Probability,
pubmed-meshheading:15566510-Recombinant Proteins,
pubmed-meshheading:15566510-Ribavirin,
pubmed-meshheading:15566510-Risk Assessment,
pubmed-meshheading:15566510-Salvage Therapy,
pubmed-meshheading:15566510-Severity of Illness Index,
pubmed-meshheading:15566510-Statistics, Nonparametric,
pubmed-meshheading:15566510-Taiwan,
pubmed-meshheading:15566510-Treatment Outcome,
pubmed-meshheading:15566510-Viral Load
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan.
|
| pubmed:affiliation |
Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|